Bess M. Flashner

Bess M. Flashner

Auto-generated profile, based on publicly available information

Bess M. Flashner

Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Chest
Verified
Journal Article
Open access
RIRyosuke Imai
Ryosuke Imai
RBRene S. Bermea
Rene S. Bermea
SZSophia H. Zhao
Sophia H. Zhao
SMSydney B. Montesi
Sydney B. Montesi
ASAnjali Singh
Anjali Singh
RHRobert Hallowell
Robert Hallowell
Identifying biomarkers is vital for interstitial lung disease (ILD) management and prognostication. While anti-Ro52 antibodies are frequently detected in autoimmune diseases, their significance in ILD remains unclear. What is the prognostic significance of anti-Ro52 positivity in patients with ILD? This retrospective cohort study used an ILD registry of patients seen at an academic tertiary hospital's ILD clinic between 2015 and 2024. All patients diagnosed with ILD and tested for anti-Ro52 antibody status were divided into anti-Ro52 positive (Anti-Ro52+) and negative (Anti-Ro52-) groups. The primary outcome was ILD progression or all-cause death. ILD progression was defined as any of the following: hospitalization due to ILD; absolute decline in forced vital capacity percent of predicted value ≥10% from baseline; or lung transplantation. Kaplan-Meier method and Cox proportional hazards regression model were used for survival analysis. Of 1,026 patients tested for the anti-Ro52 antibody (median age: 70 years; 52% male), 154 (15%) were Anti-Ro52+. Underlying ILD subtypes were as follows: interstitial pneumonia with autoimmune features (IPAF) (n = 489, 48%), connective tissue disease-ILD (n = 132, 13%), idiopathic pulmonary fibrosis (n = 103, 10%), hypersensitivity pneumonitis (n = 61, 6%), and other idiopathic ILD (n = 241, 24%). The Anti-Ro52+ group was younger (median age 67 vs. 70 years), was more likely to have CTD (28% vs. 10%) and more frequently had a copositive myositis-specific antibody (29% vs. 16%). After a median follow-up of 25.6 months, anti-Ro52+ subjects had a higher risk of ILD progression or death (hazard ratio 2.10; 95% CI, 1.61-2.73; P<0.001) and had a higher risk of lung transplant or death (hazard ratio 1.61; 95% CI, 1.11-2.35; P=0.014) on multivariable analysis. Anti-Ro52 seropositive ILD is associated with significantly worse progression-free and transplant-free survival and may inform disease prognostication and monitoring.

5 December 2019 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
BFBess M. Flashner
Bess M. Flashner
SRSheryl L. Rifas‐Shiman
Sheryl L. Rifas‐Shiman
EOEmily Oken
Emily Oken
CCCarlos A Camargo
Carlos A Camargo
TPThomas J. Platts‐Mills
Thomas J. Platts‐Mills
MRMary B. Rice
Mary B. Rice

1 January 2022 in Respiratory Medicine
Verified
Journal Article
Closed access
BFBess M. Flashner
Bess M. Flashner
Paul VanderLaanPaul VanderLaan
Paul VanderLaan
LNLina Nurhussien
Lina Nurhussien
MRMary B. Rice
Mary B. Rice
RHRobert W. Hallowell
Robert W. Hallowell

1 April 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
BFBess M. Flashner
Bess M. Flashner
SRSheryl L. Rifas-Shiman
Sheryl L. Rifas-Shiman
EOEmily Oken
Emily Oken
CCCarlos A Camargo
Carlos A Camargo
TPThomas A.E. Platts-Mills
Thomas A.E. Platts-Mills
MRMary B. Rice
Mary B. Rice
Exhaled nitric oxide fraction (FeNO) is an indicator of allergic airway inflammation. However, it is unknown how asthma, allergic rhinitis (AR) and allergic sensitisation relate toFeNO, particularly among adolescents and in overlapping conditions. We sought to determine the associations between asthma, AR, and aeroallergen immunoglobulin (Ig)E andFeNOin adolescents.We measuredFeNOamong 929 adolescents (aged 11–16 years) in Project Viva, an unselected prebirth cohort in Massachusetts, USA. We defined asthma as ever asthma physician diagnosis plus wheezing in the past year or taking asthma medications in the past month, AR as a physician diagnosis of hay fever or AR, and aeroallergen IgE as any IgE >0.35 IU·mL−1among 592 participants who provided blood samples. We examined associations of asthma, AR and IgE with percent difference inFeNOin linear regression models adjusted for sex, race/ethnicity, age and height, maternal education and smoking during pregnancy, and household/neighbourhood demographics.Asthma (14%) was associated with 97% higherFeNO(95% CI 70–128%), AR (21%) with 45% higherFeNO(95% CI 28–65%), and aeroallergen IgE (58%) with 102% higherFeNO(95% CI 80–126%) compared to those without each condition, respectively. In the absence of asthma or AR, aeroallergen IgE was associated with 75% higherFeNO(95% CI 52–101), while asthma and AR were not associated withFeNOin the absence of IgE.The link between asthma and AR withFeNOis limited to those with IgE-mediated phenotypes.FeNOmay be elevated in those with allergic sensitisation alone, even in the absence of asthma or AR.

1 September 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
LHLida P. Hariri
Lida P. Hariri
ASAmita Sharma
Amita Sharma
SNSreyankar Nandy
Sreyankar Nandy
SBSarita R. Berigei
Sarita R. Berigei
SYSatomi Yamamoto
Satomi Yamamoto
CKColleen M. Keyes
Colleen M. Keyes

5 December 2025 in European Respiratory Journal
Verified
Journal Article
Open access
RIRyosuke Imai
Ryosuke Imai
RBRene S. Bermea
Rene S. Bermea
SZSophia H. Zhao
Sophia H. Zhao
ASAnjali Singh
Anjali Singh
ASAndrew J. Synn
Andrew J. Synn
RHRobert Hallowell
Robert Hallowell
Current guidelines define progressive pulmonary fibrosis (PPF) as the presence of at least two of the following three changes within 12 months: worsening symptoms, lung function decline, or new/extending radiographic abnormalities [1, 2]. However, limiting assessment to subsequent progression may miss high-risk patients: those presenting with severely impaired lung function may meet none of the criteria if later tests remain unchanged, delaying therapy initiation and close monitoring. Therefore, we examined whether baseline forced vital capacity (FVC) was associated with an increased risk of lung transplantation or death in non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease (ILD) patients whose FVC declined by <5 percentage points predicted during the first year after diagnosis.